Guyer William sold $1.8M of CORT

Guyer William (Chief Development Officer) sold 16,300 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $113.43 ($113.18–$114.04, $1.85M total) across 2 trades on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guyer William
Published Aug 12, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The transaction is a disclosed change in insider ownership, but the article provides no new information about Corcept’s business, pipeline, or financial outlook.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 framing reduces the likelihood of a fundamental repricing catalyst.

03

What to watch

The filing does not indicate whether the officer’s remaining holdings or future scheduled sales change, and it provides no link to any new Corcept development.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, covering trades executed 2026-08-10

Background

SEC Form 4 reports an insider open-market sale by Corcept Therapeutics CDO Guyer William, executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics insider sale: CDO Guyer William sold 16,300 shares on 2026-08-10 at about $113.18 to $114.04 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades as 10b5-1 sales are pre-planned.

Evidence & confidence

The disclosure is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific fundamentals or guidance.

Market effects

Minimal; single-company insider sale does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely administrative liquidity events, so the market may overreact if it treats it as a bearish signal.

Key entities

  • Corcept Therapeutics Inc

    Company whose insider transaction is disclosed on SEC Form 4.

  • Guyer William

    Chief Development Officer who sold 16,300 shares on 2026-08-10 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.